Delivery Order SPE2DB22D3501-SPE2DB25FXF63
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) on August 18, 2025, with completion targeted for September 9, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) with a ceiling value of $3,425.95. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for completion by October 1, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's established...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg on August 28, 2025, with completion targeted by September 19, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside provisions and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Esbriet 801 mg tablets, with a ceiling value of $3,425.95 and a period of performance through May 8, 2025. This contract is not set-aside and is a firm-fixed-price delivery order. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pulmonary fibrosis medication. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical will be delivered to the contractor's location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 90-count packages of Esbriet (pirfenidone) 801 mg tablets. This is a competitive, firm fixed-price delivery order with no set-aside designation, issued on August 19, 2025, with an ultimate completion date of September 10, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation and was competitively awarded. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,311.50 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Esbriet 801 mg tablets, a medication used in the treatment of idiopathic pulmonary fibrosis. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXF63Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Esbriet 267 mg tablets (270-count packages) at a firm fixed price of $3,425.95, with completion scheduled for September 30, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier to federal medical procurement needs, particularly for military and veteran healthcare systems across multiple therapeutic domains. AmerisourceBergen Drug Corp's DLA contract vehicle enables comprehensive global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains a robust portfolio of delivery orders encompassing specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical supplies, demonstrating its capability to fulfill federal medical supply requirements through open competition. This delivery order for Esbriet, a pulmonary fibrosis treatment, reflects the vendor's ongoing role as a primary pharmaceutical supplier within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/9/25 |